Disruption of IGF signaling in early hepatocellular carcinoma and pre-clinical efficacy of anti-IGF1R blocking therapies

被引：1
|
作者：
Tovar, V. [1 ,2 ]
Alsinet, C. [1 ,2 ]
Cabellos, L. [1 ,2 ]
Sole, M. [1 ,2 ]
Villanueva, A. [3 ]
Chiang, D. [5 ]
Moyano, S. [1 ,2 ]
Schwartz, M. [3 ]
Mazzaferro, V. [4 ]
Bruix, J. [1 ,2 ]
Llovet, J. M. [1 ,2 ,3 ]
机构：
[1] IDIBAPS, Hosp Clin, Liver Unit, HCC Translat Lab,BCLC Grp, Barcelona, Spain
[2] IDIBAPS, Hosp Clin, Dept Pathol, Barcelona, Spain
[3] Mt Sinai Sch Med, Div Liver Dis, Mt Sinai Liver Canc Program, New York, NY USA
[4] Ist Nazl Tumori, I-20133 Milan, Italy
[5] Broad Inst, Canc Program, Boston, MA USA
来源：
JOURNAL OF HEPATOLOGY | 2008年 / 48卷
关键词：
D O I：
10.1016/S0168-8278(08)60004-5
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
2
引用
收藏
页码：S3 / S3
页数：1
相关论文
共 50 条
  • [41] Functional Comparison of IGF-1R Antibodies and Possible Implications for Clinical Safety and Efficacy
    Kuenkele, K. P.
    Hofmann, M. H.
    Scheiblich, S.
    Wartha, K.
    Rieder, N.
    Klein, C.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S157 - S157
  • [42] Heterodimerization of Glycosylated Insulin-Like Growth Factor-1 Receptors and Insulin Receptors in Cancer Cells Sensitive to Anti-IGF1R Antibody
    Kim, Jun Gyu
    Kang, Min Jueng
    Yoon, Young-Kwang
    Kim, Hwang-Phill
    Park, Jinah
    Song, Sang-Hyun
    Han, Sae-Won
    Park, Jong-Wan
    Kang, Gyeong Hoon
    Kang, Keon Wook
    Oh, Do Youn
    Im, Seock-Ah
    Bang, Yung-Jue
    Yi, Eugene C.
    Kim, Tae-You
    PLOS ONE, 2012, 7 (03):
  • [43] SAHA anti-neoplastic effects in Glioblastoma via IGF-1R signaling pathway
    Benzeroual, Kenza
    Dharmadhikari, Rutuja
    Mehta, Vrutti
    FASEB JOURNAL, 2021, 35
  • [44] Relevance of hypoxia-inducible factor 1 alpha in hepatocellular carcinoma: clinical and pre-clinical analysis
    Payo-Serafin, Tania
    Fernandez-Palanca, Paula
    Mendez-Blanco, Carolina
    Martinez-Geijo, Jennifer
    San Miguel de Vega, Beatriz
    Garcia-Palomo, Andres
    Jose Ortiz de Urbina, Juan
    Gonzalez-Gallego, Javier
    Maria Jesus, Tunon Gonzalez
    Luis Mauriz, Jose
    JOURNAL OF HEPATOLOGY, 2023, 78 : S554 - S555
  • [45] CD24 cell surface expression in Mvt1 mammary cancer cells serves as a biomarker for sensitivity to anti-IGF1R therapy
    Rostoker, Ran
    Ben-Shmuel, Sarit
    Rashed, Rola
    Orr, Zila Shen
    LeRoith, Derek
    BREAST CANCER RESEARCH, 2016, 18
  • [46] Pre-clinical efficacy of the Wnt pathway inhibitor RXC004 in combination with anti-cancer therapies
    Kelly, James
    Woodcock, Simon
    Bhamra, Inder
    Jones, Cliff
    Armer, Richard
    Robertson, Jane
    Phillips, Caroline
    CANCER RESEARCH, 2022, 82 (12)
  • [47] miR-455-5p suppresses hepatocellular carcinoma cell growth and invasion via IGF-1R/AKT/GLUT1 pathway by targeting IGF-1R
    Hu, Yiren
    Yang, Zhangwei
    Bao, Dandan
    Ni, Jun-Sheng
    Lou, Jian
    PATHOLOGY RESEARCH AND PRACTICE, 2019, 215 (12)
  • [48] Investigational IGF1R inhibitors in early stage clinical trials for cancer therapy
    Werner, Haim
    Sarfstein, Rive
    Bruchim, Ilan
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2019, 28 (12) : 1101 - 1112
  • [49] Abrogating the interplay between IGF2BP1, 2 and 3 and IGF1R by let-7i arrests hepatocellular carcinoma growth
    Fawzy, Injie Omar
    Hamza, Mohammed Tarif
    Hosny, Karim Adel
    Esmat, Gamal
    Abdelaziz, Ahmed Ihab
    GROWTH FACTORS, 2016, 34 (1-2) : 42 - 50
  • [50] MiR-505 suppressed the growth of hepatocellular carcinoma cells via targeting IGF-1R
    Ren, Liang
    Yao, Yongshan
    Wang, Yang
    Wang, Shengqiang
    BIOSCIENCE REPORTS, 2019, 39
12345